Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing primaquine diphosphate for imatinib-resistant chronic myeloid leukemia via targeting BCR-ABL and Wnt/β-catenin pathway.

iScience·2026
Same author

TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis.

Biology direct·2026
Same author

High-entropy multimetallic nitrogen-doped carbon for robust ammonium-ion storage.

Journal of colloid and interface science·2026
Same author

A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer.

Journal of translational medicine·2026
Same author

HVD-Net: low-light image enhancement in HSV space via continuous hue encoding and dual-branch restoration.

Scientific reports·2026
Same author

Development of a Panvascular Health Promotion and Risk Stratification Tool for Community Screening: Grounded in Four-Level Disease Prevention Theory.

Journal of multidisciplinary healthcare·2026

Related Experiment Video

Updated: Feb 19, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer.

Licai He1, Zhuanyun Du1, Xusheng Xiong1

  • 1Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325035, China.

Scientific Reports
|November 8, 2017
PubMed
Summary
This summary is machine-generated.

Androgen receptor (AR) drives growth in HER2-positive breast cancer (BC) by interacting with HER2 signaling. Anti-androgen drugs like Enzalutamide show promise as a new therapy for HER2+ BC.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Related Experiment Videos

Last Updated: Feb 19, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Androgen receptor (AR) is prevalent in breast cancer (BC) subtypes.
  • AR's role in HER2-positive (HER2+) BC remains unclear.
  • HER2+ BC requires novel therapeutic strategies.

Purpose of the Study:

  • To investigate the function of AR in HER2+ BC.
  • To evaluate the efficacy of AR inhibition on HER2+ BC cell growth.
  • To explore the therapeutic potential of anti-androgen drugs in HER2+ BC.

Main Methods:

  • Knockdown of AR using shRNAs.
  • Treatment with Enzalutamide, a novel anti-androgen drug.
  • In vitro cell growth assays and in vivo xenograft models.
  • Biochemical analysis of signaling pathways (HER2, Erk, Akt).

Main Results:

  • AR inhibition (shRNA or Enzalutamide) significantly reduced HER2+ BC cell proliferation.
  • Enzalutamide demonstrated efficacy comparable to trastuzumab in vitro and in vivo.
  • Combination therapy of Enzalutamide and trastuzumab enhanced growth inhibition.
  • AR inhibition decreased HER2 phosphorylation and downstream signaling (Erk, Akt).
  • Enzalutamide treatment reduced tumor cell proliferation (Ki67) and increased apoptosis (caspase-3) in vivo.

Conclusions:

  • AR plays a critical role in promoting HER2+ BC growth through cross-talk with HER2 signaling.
  • Enzalutamide shows significant anti-tumor activity in HER2+ BC models.
  • Anti-androgen therapy represents a potential alternative or supplementary treatment for HER2+ BC.